Dyne Therapeutics, Inc.
DYNNext catalyst
Zeleciment Rostudirsen (DYNE-251)
DMD who are amenable to exon 51 skipping
Get an email about DYN's next catalysts
Track Dyne Therapeutics (DYN) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 1 past
FDA PDUFA Date zeleciment rostudirsen (DYNE-251) (priority)
For DMD who are amenable to exon 51 skipping. bla filing. Extracted from SEC filing: EX-99.1
SourceUpcoming FDA decisions
Market Overview
Stock performance and key metrics
zeleciment basivarsen (DYNE-101)
Myotonic Dystrophy Type 1 (DM1)
Zeleciment Rostudirsen (DYNE-251)
Duchenne Muscular Dystrophy (DMD)
DYNE-101
Myotonic Dystrophy Type 1 (DM1)
DYNE-251
Duchenne Muscular Dystrophy (DMD)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
zeleciment basivarsen (DYNE-101) | Phase 3 | Myotonic Dystrophy Type 1 (DM1) | - | - |
Zeleciment Rostudirsen (DYNE-251) | Phase 3 | Duchenne Muscular Dystrophy (DMD) | - | - |
DYNE-101 | Phase 2 | Myotonic Dystrophy Type 1 (DM1) | - | - |
DYNE-251 | Phase 2 | Duchenne Muscular Dystrophy (DMD) | - | - |
Frequently asked questions
What is in Dyne Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Dyne Therapeutics, Inc.'s (DYN) pipeline across Phase 3, Phase 2. Its lead program is Zeleciment Rostudirsen (DYNE-251) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Dyne Therapeutics, Inc.'s next FDA catalyst?→
Dyne Therapeutics, Inc.'s (DYN) next tracked catalyst is a PDUFA date expected Jan 21, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track DYN biotech catalysts?→
Add DYN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Dyne Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.